{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "f1b361c7",
   "metadata": {
    "pilot_cell_id": "15cbc0e6-2136-4dfa-8243-b5af972ddd39"
   },
   "source": [
    "Total: 100 points"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a4f64238",
   "metadata": {
    "pilot_cell_id": "231b6878-ff11-4ce5-8631-209414548100"
   },
   "source": [
    "1) States the analysis goal.\n",
    "- 10: Clearly states the goal (baseline circulating biomarkers predictive of OS by regimen), distinguishes arm-specific vs shared, and names all three modalities (flow cytometry/X50, CyTOF, Olink).\n",
    "- 5: States the goal but misses modality(ies) or the arm-specific/shared framing.\n",
    "- 0: Goal is incorrect or unclear."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e494cc66",
   "metadata": {},
   "source": [
    "2) Loads required input data and performs basic sanity checks.\n",
    "- 10: Loads clinical and all available platform datasets, reports dimensions/heads, and correctly restricts to baseline timepoint (e.g., C1D1).\n",
    "- 5: Loads most inputs but baseline restriction or completeness is unclear.\n",
    "- 0: Data loading is largely missing or incorrect."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c0173c83",
   "metadata": {
    "pilot_cell_id": "362f01ed-986f-4b79-a9e7-c1026cbba3f0"
   },
   "source": [
    "3) Correctly merges biomarkers with clinical survival data.\n",
    "- 10: Uses the correct patient-level identifier (Deidentified.ID), avoids double-counting, and reports final sample sizes.\n",
    "- 5: Merge is mostly correct but patient-level deduplication or key usage is incomplete.\n",
    "- 0: Merge is incorrect (wrong key, duplicated patients, or OS misaligned)."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a50c9c7f",
   "metadata": {},
   "source": [
    "4) Defines and applies treatment arms consistently.\n",
    "- 10: Correctly defines nivo/chemo and sotiga/chemo arms and filters to evaluable patients per platform, reporting per-arm n.\n",
    "- 5: Arm definitions are present but filtering or reporting is incomplete.\n",
    "- 0: Arm assignment is incorrect or absent."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "6b8d2804",
   "metadata": {},
   "source": [
    "5) Performs within-arm survival screening.\n",
    "- 10: For each arm and platform, performs Cox proportional hazards modeling using a within-arm median high/low split and reports HRs and p-values.\n",
    "- 5: Cox models are run but split definition or reporting is incomplete.\n",
    "- 0: Survival modeling is missing or incorrect."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "588fcddb",
   "metadata": {},
   "source": [
    "6) Applies multiple-testing correction appropriately.\n",
    "- 10: Applies BH-FDR correction within each platform and arm and defines significance using q ≤ 0.10.\n",
    "- 5: FDR is applied but inconsistently or with an unclear scope/threshold.\n",
    "- 0: No multiple-testing correction."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "96223456",
   "metadata": {},
   "source": [
    "7) Compiles significant biomarkers by arm and platform.\n",
    "- 10: Produces a clear compilation of significant biomarkers per arm across flow cytometry, CyTOF, and Olink, explicitly noting platforms with no hits.\n",
    "- 5: Compilation is partial or missing a platform.\n",
    "- 0: No compilation step."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b41cf51a",
   "metadata": {},
   "source": [
    "8) Categorizes biomarkers as arm-specific or shared.\n",
    "- 10: Clearly defines “shared” (significant in both arms with concordant direction) and applies this classification to all results.\n",
    "- 5: Mentions arm-specific vs shared but definition or labeling is incomplete.\n",
    "- 0: No arm-specific/shared categorization."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5a079527",
   "metadata": {},
   "source": [
    "9) Evaluates treatment specificity using interaction testing.\n",
    "- 10: Performs biomarker × treatment arm interaction testing and reports interaction statistics and FDR results.\n",
    "- 5: Interaction testing is attempted but reporting or correction is incomplete.\n",
    "- 0: No interaction analysis."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "30e538c8",
   "metadata": {},
   "source": [
    "10) Provides interpretation and limitations.\n",
    "- 10: Interprets arm-specific biomarkers with biologically grounded rationale linked to mechanism (CD40 agonist vs PD-1 blockade) and clearly states key data limitations (sample size, multiple testing, interaction power).\n",
    "- 5: Provides either biological rationale or limitations, but not both.\n",
    "- 0: No meaningful interpretation or limitations discussion."
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
